BCDD and EU-OPENSCREEN aiming for cooperation
Israeli researchers visited EU-OPENSCREEN headquarters and FMP Germany to discuss future collaborations
BCDD staff researchers, Avi Raveh, Eddy Pichinuk and Hamutal Engel, visited last week at the EU-OPENSCREEN headquarters and at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, Germany, to meet Dr. Wolfgang Kappe, EU-OPENSCREEN Director General and Dr. Philip Brennecke, EU-OPENSCREEN Scientific Project Officer, to discuss collaboration opportunities.
The BCDD team, along with Dr. Jens von Kries, Director of the FMP Screening Unit, attended the screening facilities and learned about the compound management system from Dr. Edgar Specker, a member of the FMP Medicinal Chemistry group. Both sides are now believing that the meeting is a stepping stone for future cooperation.
EU-OPENSCREEN is a part of the European Research Infrastructure Consortium (ERIC), founded in April 2018 by seven European countries: Czech Republic, Finland, Germany, Latvia, Norway, Poland, and Spain. EU-OPENSCREEN offers researchers from Europe and around the world open access to a uniquely broad range of high technologies and tools for the systematic screening of chemical substances for their biological effects.
The BCDD, the Nancy and Stephen Grand Israel National Center for Personalized Medicine (G-INCPM), and Galilee Technology Center (MIGAL) were recently accepted as EU-OPENSCREEN potential partner sites for screening and medicinal chemistry services.